Churchill, Grayson-JC Fund Lasix Studies

Churchill Downs, Inc. announced Sept. 17 that the Kentucky-based racetrack operator, working in partnership with the Grayson-Jockey Club Research Foundation, other leading racetrack operators, and the American Association of Equine Practitioners, has committed funds for studies of the administration of furosemide in Thoroughbred racehorses.

 

Simultaneous studies on the physiology of exercise induced pulmonary hemorrhaging and the effects of its best-known medical treatment, furosemide (commonly known as Lasix or Salix), are being conducted by the University of California-Davis and Washington State University. Overall funding for the studies includes contributions from the AAEP, CDI, and other race track operators. 

 

"These studies can be best described as progress toward an industry-wide answer to this race-day medication question," said Mike Ziegler, executive director of racing for CDI. "The ongoing industry debate on the use of Lasix has been underway for decades. We believe this research is a step in the right direction, using science to drive the conversation. Churchill Downs is proud to participate alongside other key players in our industry in the funding of these studies."

 

"The scientific community is poised to provide answers to challenging questions long asked by the Thoroughbred industry," said Dell Hancock, chairman of Grayson-Jockey Club. "Support of this research proves there is a desire to work together to address important industry issues. We are appreciative for the commitment Churchill Downs Incorporated has made to this effort."